ipamorelin — Growth hormone releasing hormone (GHRH) analog + Growth hormone secretagogue (GHS)
CJC-1295: GHRH analog that binds GHRH receptor to stimulate pituitary GH release with extended half-life via DAC (Drug Affinity Complex) or albumin binding. Ipamorelin: Selective ghrelin mimetic (GHSR agonist) that stimulates GH release without significant cortisol or prolactin elevation. Combined: synergistic GH pulse amplification.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Growth hormone releasing hormone (GHRH) analog + Growth hormone secretagogue (GHS)
Mechanism of Action
CJC-1295: GHRH analog that binds GHRH receptor to stimulate pituitary GH release with extended half-life via DAC (Drug Affinity Complex) or albumin binding. Ipamorelin: Selective ghrelin mimetic (GHSR agonist) that stimulates GH release without significant cortisol or prolactin elevation. Combined: synergistic GH pulse amplification.
Regulatory Status
Not FDA approved; research peptides
Evidence Level
Moderate — Phase 2 trials for CJC-1295; Ipamorelin Phase 2 completed; limited large-scale human data